CRDF — Cardiff Oncology, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1213037 ·
Last close
$0.85
Market Cap
$65.85M
52W High
$3.31
52W Low
$0.71
ADV30
1,291,952
Next earnings
2026-11-12
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 171,000 — -9,219,000 -8,857,000 36,414,000 12,060,000 8,316,000
Jun 2026 104,000 — -9,615,000 -9,232,000 37,329,000 9,197,000 10,797,000
Mar 2026 41,000 — -12,850,000 -12,345,000 49,172,000 8,544,000 14,463,000
Dec 2025 243,000 — -7,827,000 -7,216,000 61,884,000 17,470,000 16,496,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-40,854,000
Investing CF
$36,435,000
Financing CF
$2,832,000
CapEx
$-18,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.70
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-451,607,000
Inventory
—
Receivables
$189,000
ST Investments
$25,323,000
EBIT TTM
$-42,266,000
Pretax Income TTM
$-40,051,000
Interest Exp TTM
—
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$508,000
EBITDA
$-41,915,000
Free Cash Flow
$-24,304,250
Enterprise Value
$22,540,824
Total Cash
$34,520,000
Total Debt
$457,000
Shares Out
77,795,249
Trailing EPS
$-0.54
Book Value
$0.66
ROE
-94.1%
ROA
-46.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 593,000 -48,960,000 -45,851,000 61,884,000 16,496,000 45,388,000 -37,923,000
Dec 2024 683,000 -48,651,000 -45,431,000 97,190,000 14,241,000 82,949,000 -37,693,000
Dec 2023 488,000 -45,412,000 -41,441,000 81,637,000 11,898,000 69,739,000 -30,887,000
Dec 2022 386,000 -39,902,000 -38,704,000 116,191,000 9,848,000 106,343,000 -33,820,000

TTM Snapshot

Revenues TTM
$508,000
NetIncome TTM
$-40,051,000
OpCashFlow TTM
—
Assets (Latest)
$37,329,000
Forward EPS
$-0.52

Max Pain — expiry 2027-01-15

max pain strike: $1.00 · spot: $0.84 · call oi: 6,430 · put oi: 63
Expected Move to 2027-01-15: ±$0.62 (74.40%) — implied range $0.21 – $1.46 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ATRA Atara Biotherapeutics, Inc. $66.22M $6.50 —
CSBR CHAMPIONS ONCOLOGY, INC. $63.91M $4.59 —
VISK Viskase Holdings, Inc. $63.49M $4.43 —
AVXL ANAVEX LIFE SCIENCES CORP. $68.60M $0.74 —
NMRA Neumora Therapeutics, Inc. $62.85M $0.33 —

News headlines (Yahoo Finance, 1h cache)

Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
2026-11-16 12:00 · Yahoo
Cardiff Oncology: Q3 Earnings Snapshot
2026-11-12 12:21 · Yahoo
Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update
2026-11-12 12:00 · Yahoo
Cardiff Oncology to Participate in the UBS Global Biopharma Conference
2026-11-03 12:00 · Yahoo
Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
2026-10-27 20:05 · Yahoo
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
2026-10-21 20:05 · Yahoo
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
2026-09-14 12:30 · Yahoo
Cardiff Oncology to Participate in September 2026 Conferences
2026-09-02 11:00 · Yahoo
CRDF: Second Quarter Earnings
2026-08-17 09:47 · Yahoo
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
2026-08-11 20:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.